NewAmsterdam Pharma Company N.V. (NAMS) fair value analysis
Nasdaq · Updated 2026-10-19
NAMS price how computed
Valuation status
No fair-value estimate yetNAMS has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for NAMS yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $19.83
- Sector
- Healthcare
- 12-month range
- $19.83–$41.45
- Market cap
- $2.37B
- From 52-week high
- -52.2%
- Shares outstanding
- 120M
- Rank in Healthcare by quality score
- #137 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
NewAmsterdam Pharma Company N.V. is a pharmaceutical company that develops and commercializes medicines, with a focus on addressing cardiovascular and metabolic diseases. The company is based in the Netherlands and operates internationally, including in the United States market.
NAMS currently ranks #137 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.37B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $7.12M
- Net margin
- -3644.2%
- EPS (TTM)
- $-1.90
- Gross margin
- 100.0%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 8.6%
- Shares outstanding
- 120M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 38 · neutral
- 50-day average
- $24.24
- 200-day average
- $30.47
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-8.3%)
2026-03 ▲ beat (+17.1%)
2025-12 ▼ miss (-57.5%)
2025-09 ▼ miss (-7.9%)
2025-06 ▲ beat (+69.8%)
2025-03 ▲ beat (+31.8%)
2024-12 ▲ beat (+3.1%)
2024-09 ▲ beat (+64.4%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 15 buy · 1 hold · 0 sell (16 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $49.9
- Target vs last price
- +151.6%
What our data shows for NAMS
- Shares are trading in the lower third of their 12-month price range of $19.83–$41.45.
- The 14-day relative strength index sits at a neutral 38.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- NAMS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the NAMS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is NAMS stock undervalued?
TickrTrends has no fair-value estimate for NAMS yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is NAMS's TickrTrends verdict?
NAMS is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does NAMS compare to other Healthcare stocks?
NAMS ranks #137 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is NAMS overbought or oversold?
NAMS's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does NAMS report earnings next?
NAMS's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does NAMS usually beat earnings estimates?
Over its last 8 reported quarters NAMS beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NAMS?
Of 16 analysts covering NAMS, 15 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $49.9 (+151.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.